Evidence map›Paper›PMID 42807979›Full record

ArticleRSC advances2026

Design, synthesis and network pharmacology-integrated evaluation of benzenesulfonamides as potential Dickkopf-1 (Dkk-1)-targeting anticancer candidates.

Syeda Abida Ejaz, Muhammad Sajjad Bilal, Pervaiz Ali Channar, Rabail Ujan, Sadia Naseem, Aamer Saeed, Sajid Ali Channar, Reshma Sahito, Qamar Abbas

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Syeda Abida EjazDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur Bahawalpur 63100 Pakistan abida.ejaz@iub.edu.pk +923336221538.ORCID https://orcid.org/0000-0002-8516-7234
Muhammad Sajjad BilalDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur Bahawalpur 63100 Pakistan abida.ejaz@iub.edu.pk +923336221538.
Pervaiz Ali ChannarDepartment of Basic Sciences and Humanities, Faculty of Basic and Allied Sciences, Dawood University of Engineering and Technology Karachi 74800 Pakistan pervaiz.ali@duet.edu.pk.
Rabail UjanDepartment of MRC/ORIC, Liaquat University of Medical & Health Sciences Jamshoro Pakistan.
Sadia NaseemDepartment of Chemistry, Quaid-I-Azam University Islamabad 45320 Pakistan asaeed@qau.edu.pk.
Aamer SaeedDepartment of Chemistry, Quaid-I-Azam University Islamabad 45320 Pakistan asaeed@qau.edu.pk.ORCID https://orcid.org/0009-0003-9432-1445
Sajid Ali ChannarDepartment of MRC, Liaquat University of Medical & Health Sciences Jamshoro Pakistan.
Reshma SahitoDepartment of Zoology University of Sindh Jamshoro Pakistan.
Qamar AbbasDepartment of Biology, College of Science, University of Bahrain Sakhir 32038 Kingdom of Bahrain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulfanilamide-based drugs are known to exhibit immense anti-cancer activities, and thus, we sought to design and formulate sulfanilamide derivatives in order to study their potential against carbonic anhydrase II, pancreatic elastase, Dickkopf-1 (Dkk1) and LRP6 proteins, which are potential anti-cancer targets for various cancers. Out of all the synthesized derivatives, compound 4d exhibited significant inhibitory potential against CA-II, with an IC

Identifiers

PMID42807979
PMCPMC13618357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.